Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy

被引：21

作者：

Li, Qing ^{[1
,2
]}

Huang, Jingcao ^{[1
,2
]}

Ou, Yang ^{[1
,2
]}

Li, Yan ^{[1
,2
]}

Wu, Yu ^{[1
,2
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu 610041, Sichuan, Peoples R China

[2] Sichuan Univ, West China Hosp, Hematol Res Lab, Chengdu 610041, Sichuan, Peoples R China

来源：

IMMUNOTHERAPY | 2019年 / 11卷 / 04期

基金：

中国国家自然科学基金;

关键词：

CD20; chidamide; diffuse large B-cell lymphoma; immunochemotherapy; immunomodulator; thalidomide; TP53; mutation; OPEN-LABEL; PHASE-II; P53; GENE; LENALIDOMIDE; RITUXIMAB; MULTICENTER; DLBCL; CHOP;

D O I：

10.2217/imt-2018-0083

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We attempted to explore novel treatment options for progressive diffuse large B-cell lymphoma (DLBCL) with TP53 mutation that has a poor response to rituximab-based immunochemotherapy. Herein, we report the case of a patient with DLBCL having TP53 mutation who showed progression following four cycles of rituximab-based immunochemotherapy but achieved sustained partial remission following chidamide-based chemotherapy. In vitro experiments performed using the DLBCL cell lines OCI-ly1 (LY1; mutant TP53), OCI-ly10 (LY10; wild-type TP53) and OCI-ly19 (LY19, wild-type TP53) demonstrated that chidamide is more potent against cells with mutant TP53 mutant than those with wild-type TP53. Moreover, chidamide can reduce the mRNA and protein expression levels of mutant TP53 and upregulate the surface expression of the CD20 antigen in lymphoma cells.

引用

页码：265 / 272

页数：8

共 26 条

[1] Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte [J].

Coiffier, Bertrand ;

Thieblemont, Catherine ;

Van Den Neste, Eric ;

Lepeu, Gerard ;

Plantier, Isabelle ;

Castaigne, Sylvie ;

Lefort, Sophie ;

Marit, Gerald ;

Macro, Margaret ;

Sebban, Catherine ;

Belhadj, Karim ;

Bordessoule, Dominique ;

Ferme, Christophe ;

Tilly, Herve .

BLOOD, 2010, 116 (12) :2040-2045

[2] Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: Low-dose metronomic, multidrug therapy [J].

Coleman, Morton ;

Martin, Peter ;

Ruan, Jia ;

Furman, Richard ;

Niesvizky, Ruben ;

Elstrom, Rebecca ;

George, Patricia ;

Kaufman, Thomas P. ;

Leonard, John R. .

CANCER, 2008, 112 (10) :2228-2232

[3] Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells [J].

Fernandez-Rodriguez, Concepcion ;

Salar, Antonio ;

Navarro, Alfons ;

Gimeno, Eva ;

Pairet, Silvia ;

Camacho, Laura ;

Ferraro, Mariana ;

Serrano, Sergi ;

Besses, Carles ;

Bellosillo, Beatriz ;

Sanchez-Gonzalez, Blanca .

LEUKEMIA & LYMPHOMA, 2016, 57 (03) :692-699

[4] Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response [J].

Houldsworth, Jane ;

Petlakh, Marina ;

Olshen, Adam B. ;

Chaganti, R. S. K. .

LEUKEMIA & LYMPHOMA, 2008, 49 (11) :2163-2173

[5] Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma [J].

Ichikawa, A ;

Kinoshita, T ;

Watanabe, T ;

Kato, H ;

Nagai, H ;

Tsushita, K ;

Saito, H ;

Hotta, T .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (08) :529-534

[6] Thalidomide enhanced the efficacy of CHOP chemotherapy in the treatment of diffuse large B cell lymphoma: A phase II study [J].

Ji, Dongmei ;

Li, Qiu ;

Cao, Junning ;

Guo, Ye ;

Lv, Fangfang ;

Liu, Xiaojian ;

Wang, Biyun ;

Wang, Leiping ;

Luo, Zhiguo ;

Chang, Jianhua ;

Wu, Xianghua ;

Hong, Xiaonan .

ONCOTARGET, 2016, 7 (22) :33331-33339

[7] Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma [J].

Kurtz, David M. ;

Scherer, Florian ;

Jin, Michael C. ;

Soo, Joanne ;

Craig, Alexander F. M. ;

Esfahani, Mohammad Shahrokh ;

Chabon, Jacob J. ;

Stehr, Henning ;

Liu, Chih Long ;

Tibshirani, Robert ;

Maeda, Lauren S. ;

Gupta, Neel K. ;

Khodadoust, Michael S. ;

Advani, Ranjana H. ;

Levy, Ronald ;

Newman, Aaron M. ;

Duehrsen, Ulrich ;

Huettmann, Andreas ;

Meignan, Michel ;

Casasnovas, Rene-Olivier ;

Westin, Jason R. ;

Roschewski, Mark ;

Wilson, Wyndham H. ;

Gaidano, Gianluca ;

Rossi, Davide ;

Diehn, Maximilian ;

Alizadeh, Ash A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2845-+

[8] Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas [J].

Kwok, Mary ;

Wu, S. Peter ;

Mo, Clifton ;

Summers, Thomas ;

Roschewski, Mark .

CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (09)

[9] p53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas [J].

Leroy, K ;

Haioun, C ;

Lepage, E ;

Le Métayer, N ;

Berger, F ;

Labouyrie, E ;

Meignin, V ;

Petit, B ;

Bastard, C ;

Salles, G ;

Gisselbrecht, C ;

Reyes, F ;

Gaulard, P .

ANNALS OF ONCOLOGY, 2002, 13 (07) :1108-1115

[10] The P53 pathway: what questions remain to be explored? [J].

Levine, A. J. ;

Hu, W. ;

Feng, Z. .

CELL DEATH AND DIFFERENTIATION, 2006, 13 (06) :1027-1036

← 1 2 3 →